Gilead Sciences (NASDAQ:GILD) Price Target Raised to $171.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by Morgan Stanley from $150.00 to $171.00 in a research report report published on Wednesday,MarketScreener reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on GILD. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Argus lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Daiwa Securities Group increased their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Wolfe Research raised their price objective on Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Finally, Needham & Company LLC lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $152.42.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $154.98 on Wednesday. The stock has a 50 day simple moving average of $130.27 and a 200 day simple moving average of $122.27. The stock has a market cap of $192.28 billion, a P/E ratio of 22.89, a PEG ratio of 1.22 and a beta of 0.36. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter last year, the business earned $1.90 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 319,391 shares of company stock worth $44,141,101 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after buying an additional 2,113,692 shares during the last quarter. State Street Corp boosted its holdings in shares of Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank bought a new stake in Gilead Sciences during the 4th quarter worth $2,617,152,000. Finally, Invesco Ltd. increased its holdings in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.